Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$15.82
+0.2%
$13.57
$7.08
$17.49
$327.59M0.8283,881 shs48,413 shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$24.45
+3.5%
$15.46
$10.80
$24.54
$353.94M-0.0497,722 shs203,945 shs
Metagenomi, Inc. stock logo
MGX
Metagenomi
$1.99
-6.6%
$1.69
$1.23
$5.10
$74.39M-0.38883,139 shs430,697 shs
Moderna, Inc. stock logo
MRNA
Moderna
$31.26
-2.9%
$27.91
$23.15
$125.68
$12.09B1.848.97 million shs7.81 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%-6.56%+18.68%+73.66%+1.41%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
0.00%+12.31%+60.75%+113.16%+75.77%
Metagenomi, Inc. stock logo
MGX
Metagenomi
0.00%-8.72%+34.46%+30.92%-61.58%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-7.07%+23.07%+26.48%-74.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amarin Corporation PLC stock logo
AMRN
Amarin
0.3962 of 5 stars
0.53.00.00.02.70.00.6
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
3.0615 of 5 stars
0.03.00.04.63.32.51.3
Metagenomi, Inc. stock logo
MGX
Metagenomi
2.9406 of 5 stars
3.54.00.00.01.91.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.2516 of 5 stars
4.01.00.04.61.82.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
1.00
Sell$12.00-24.15% Downside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.00
HoldN/AN/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
3.00
Buy$13.00553.27% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6149.11% Upside

Current Analyst Ratings Breakdown

Latest MGX, MRNA, AMRN, and INBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight
7/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold ➝ Hold
6/25/2025
Amarin Corporation PLC stock logo
AMRN
Amarin
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$7.00 ➝ $12.00
6/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$33.00 ➝ $26.00
5/15/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/15/2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $12.00
5/14/2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$20.00 ➝ $16.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $70.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$45.00 ➝ $40.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$214.11M1.53N/AN/A$23.62 per share0.67
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$200K1,769.69$116.43 per share0.21$9.23 per share2.65
Metagenomi, Inc. stock logo
MGX
Metagenomi
$45.26M1.64N/AN/A$6.28 per share0.32
Moderna, Inc. stock logo
MRNA
Moderna
$3.14B3.85N/AN/A$28.33 per share1.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$82.18M-$3.64N/AN/AN/A-41.07%-17.21%-12.16%7/30/2025 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.69B$116.750.21N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$78.06M-$2.11N/AN/AN/A-172.21%-31.21%-22.21%8/13/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%8/1/2025 (Estimated)

Latest MGX, MRNA, AMRN, and INBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.62N/AN/AN/A$7.72 millionN/A
8/12/2025Q2 2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.92N/AN/AN/AN/AN/A
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.97N/AN/AN/A$116.26 millionN/A
7/30/2025Q2 2025
Amarin Corporation PLC stock logo
AMRN
Amarin
-$0.60N/AN/AN/A$45.45 millionN/A
5/14/2025Q4 2024
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.55-$2.80-$0.25-$2.80N/AN/A
5/13/2025Q1 2025
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.62-$0.68-$0.06-$0.68$8.75 million$4.13 million
5/7/2025Q1 2025
Amarin Corporation PLC stock logo
AMRN
Amarin
-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.53
2.55
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.04
5.12
5.12
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
5.85
5.85
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
3.30%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
17.09%
Metagenomi, Inc. stock logo
MGX
Metagenomi
17.80%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
36020.71 million20.02 millionOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.48 million12.00 millionOptionable
Metagenomi, Inc. stock logo
MGX
Metagenomi
23637.38 million30.73 millionN/A
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable

Recent News About These Companies

Moderna cancels Japan mRNA plant plans amid weak demand
William Blair Estimates Moderna's Q2 Earnings (NASDAQ:MRNA)
Moderna patent for mRNA vaccine knocked back, for now
Moderna: Ready For The Redemption Arc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$15.82 +0.03 (+0.19%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$15.90 +0.07 (+0.47%)
As of 07/18/2025 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$24.45 +0.83 (+3.51%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$24.45 0.00 (0.00%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Metagenomi stock logo

Metagenomi NASDAQ:MGX

$1.99 -0.14 (-6.57%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.00 +0.01 (+0.75%)
As of 07/18/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$31.26 -0.94 (-2.92%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$31.26 -0.01 (-0.02%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.